(+)-4-Propyl-9-hydroxynaphthoxazine in Parkinson's disease.
Grandas Perez
F J
FJ
Jenner
P G
PG
Nomoto
M
M
Stahl
S
S
Quinn
N P
NP
Parkes
J D
JD
Critchley
P
P
Marsden
C D
CD
D000818:Animals; D002144:Callithrix; D002230:Carbidopa / Q000008:administration & dosage; D004294:Domperidone / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage; D010078:Oxazines / Q000008:administration & dosage / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D013997:Time Factors
C043445:4-propyl-7-hydroxy-1,2,3,4a,5,6-hexahydronaphthoxazine; D004338:Drug Combinations; D010078:Oxazines; C009265:carbidopa, levodopa drug combination; D007980:Levodopa; D004294:Domperidone; D002230:Carbidopa